SEP 16, 2015 7:00 AM PDT

Editas Medicine, Creating a novel class of genome editing therapeutics


Genome editing technologies, including the CRISPR/Cas9 system, allow for precise and corrective molecular modifications to treat the underlying cause of genetic diseases. Editas Medicine is developing CRISPR/Cas9-based therapeutics across abroad range of indications. This presentation will focus on Editas'approach to CRISPR technology optimization within the context of specific ex vivo and in vivo therapeutic applications

You May Also Like
Loading Comments...